Table II.

Correlation between EGFR/KRAS mutation status and ALK rearrangement with the histological subtype.

	EGFR			KRAS			ALK rearrangement
Predominant subtypea	Mutation	WT	P-value	Mutation	WT	P-value	Positive	Negative	P-value
Lepidic predominant
Yes	3	0		0	0		0	0
No	89	108		18	182		23	177
Acinar predominant
Yes	43	34	0.030	1	76	0.002	6	71	0.256
No	49	74		17	106		17	106
Papillary predominant
Yes	26	23	0.038	3	46	0.120	1	48	0.004
No	66	85		15	136		22	129
Micropapillary predominant
Yes	4	3		0	7		2	5
No	88	105		18	175		21	172
Solid predominant
Yes	15	37	0.006	9	43	0.023	13	39	0.002
No	77	71		9	139		10	138
Invasive mucinous adenocarcinoma
Yes	1	9	0.040	5	5	0.004	1	9	1.000
No	91	99		13	177		22	168

^aThe predominant subtype according the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. Only patients with acinar predominant, papillary predominant, solid predominant with mucin production and invasive mucinous adenocarcinoma were analyzed, since cases with lepidic and micropapillary predominant subtypes were too few (5 and 7 cases, respectively. EGFR, epidermal growth factor receptor; KRAS, Kirsten rat sarcoma viral oncogene homolog; ALK, anaplastic lymphoma receptor tyrosine kinase; WT, wild-type.